MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, KURA had -$110,016K decrease in cash & cash equivalents over the period. -$85,982K in free cash flow.

Cash Flow Overview

Change in Cash
-$110,016K
Free Cash flow
-$85,982K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Share-based compensation expense
    • Operating lease liabilities
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Net loss
    • Accrued expenses and other curre...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue
-67,482 --
Total operating expenses
-371,113 --
Interest and other income, net
-26,774 --
Interest expense
-1,512 --
Income tax expense
-297 --
Net loss
-73,333 -80,999 -74,116 -123,551
Share-based compensation expense
8,416 11,352 10,965 14,791
Accounts payable and accrued expenses
--12,716 2,098
Amortization of premium and accretion of discounts on short-term investments, net
900 1,382 1,924 5,182
Depreciation expense
355 403 164 465
Non-cash interest expense
106 103 141 271
Accounts receivable, net
544 6,744 --
Receivable from contracts with collaborators
--31,362 2,514
Inventory
430 413 --
Prepaid expenses and other current assets
562 -2,890 10,289 8,551
Operating lease right-of-use and other long-term assets
-689 558 2,883 2,922
Accounts payable
2,026 4,499 --
Accrued expenses and other current liabilities
-16,216 12,654 --
Operating lease liabilities
3,778 ---
Other long-term liabilities
204 118 297 628
Contract liabilities
-9,443 156,288 15,664 23,763
Net cash used in operating activities
-85,854 117,273 -80,627 -100,704
Purchases of short-term investments
171,601 239,775 138,499 383,314
Maturities of short-term investments
147,498 177,500 235,032 342,596
Purchases of property and equipment
128 2,321 2,567 1,750
Net cash used in investing activities
-24,231 -64,596 93,966 -42,468
Proceeds from issuance of stock under equity plans
69 1,135 0 658
Proceeds from issuances of common stock and pre-funded warrants, net of offering costs
-0 --
Net cash provided by financing activities
69 1,135 0 658
Net decrease in cash and cash equivalents
-110,016 53,812 13,339 -142,514
Cash and cash equivalents at beginning of period
149,099 95,287 224,462 -
Cash and cash equivalents at end of period
39,083 149,099 95,287 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofstock under equity...$69K Net cash provided byfinancing activities$69K Net decrease in cashand cash...-$110,016K Canceled cashflow$69K Share-based compensationexpense$8,416K Operating leaseliabilities$3,778K Accounts payable$2,026K Operating leaseright-of-use and other...-$689K Depreciation expense$355K Other long-termliabilities$204K Non-cash interestexpense$106K Maturities of short-terminvestments$147,498K Net cash used inoperating activities-$85,854K Net cash used ininvesting activities-$24,231K Canceled cashflow$15,574K Canceled cashflow$147,498K Net loss-$73,333K Accrued expenses andother current...-$16,216K Purchases of short-terminvestments$171,601K Contract liabilities-$9,443K Amortization of premium andaccretion of discounts on...$900K Prepaid expenses andother current assets$562K Accounts receivable, net$544K Inventory$430K Purchases of property andequipment$128K

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA)